New ipratropium formulation to decrease nebulization time

doi:10.1016/j.rmed.2006.05.015

Return

New ipratropium formulation to decrease nebulization time

2007-02-01

DOI：10.1016/j.rmed.2006.05.015

Original

Save

View PDF

Abstract

En 中文

A new anticholinergic aerosol containing 0.5mg ipratropium bromide dissolved in 1 mL of solution has been produced with the purpose of decreasing nebulization time for patients compared to the traditional formulation which is twice as voluminat (0.5mg/2mL, Boehringer-Ingetheim, France). The aim of this study was to compare aerosol characteristics (inhaled mass, particle size distribution and nebulization time) of these two formulations of ipratropium bromide, nebulized alone and with terbutatine (5mg/2mL, Astra Zeneca, Sweden), to determine whether the new formulation was equivalent to the old one. Four different jet nebutizers were used: PariLC+(R), Atomisor NL9M (R), Sidestream (R) and Mistyneb (R). Statistical analysis of the results showed that for all types of nebulizer, the inhaled mass of ipratropium bromide 0. 5 mg/ 1 mL was significantly lower than the inhaled mass of ipratropium bromide 0.5mg/2mL, and that there was no statistical difference between the inhaled mass of ipratropium bromide 0. 5 mg/ 1 mL+terbutaline 5 mg/2 mL and the inhaled mass of ipratropium bromide 0. 5 mg/2 mL+terbutatine 5mg/2mL. The study also showed that the new formulation of ipratropium bromide (0.5mg/lmL) mixed with terbutatine allowed a 26% decrease in nebulization time compared to the old formulation (0.5mg/2mL) mixed with terbutaline without changing aerosol characteristics (inhaled mass and particle size distribution). This Leads to the conclusion that a 2 mL minimum volume is required for nebulization, and that nebulization of ipratropium bromide 0.5mg/1 mL alone must be avoided. (c) 2006 Elsevier Ltd. All rights reserved.

Keywords:

aerosol

jet nebulizer

anticholinergic

ipratropium bromide

terbutaline

nebulization time

AI Summary

Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.